Skip to main content Skip to main navigation menu Skip to site footer

Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD)

  • Putu Nita Cahyawati ,
  • I Nyoman Mantik Astawa ,
  • Bagus Komang Satriyasa ,
  • I Made Bakta ,

Abstract

Link of Video: https://youtu.be/KtNkkeJmbh4

Background:
Chronic kidney disease (CKD) is a progressive disease whose prevalence increases annually. Studies in recent years report that statins (hydroxy-3-nethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) affect preventing the progression of kidney damage, in addition to their ability to prevent cardiovascular risk in patients with CKD. This study aims to determine the effect of statins on kidney function and renal fibrosis in chronic kidney disease.

Methods: This research is pure experimental (randomized post-test only control group design). The research sample consisted of 20 white mice (Mus musculus L.), Swiss line, aged 3-4 months, and weight 30-40 grams. Samples were randomly grouped into four treatment groups: control (K, n = 5), treatment with simvastatin at a dose of 5.2 mg/kgBW (P1), treatment with simvastatin at a dose of 10.4 mg/kgBW (P2), and treatment with simvastatin at a dose of 20.8 mg/kgBW (P3). Interstitial fibrosis was assessed using Picrosirus Red staining. Data analysis used One-Way ANOVA and Tukey's post hoc tests with a significance value of p<0.05 in SPSS version 25.0 for Windows.

Results: The results showed that the control group (K) was the group with the highest serum creatinine level (1.07 ± 0.43) compared to the other treatment groups (p <0.05). Administration of simvastatin at doses of 5.2 mg/kgBW, 10.4 mg/kgBW, and 20.8 mg/kg BW in CKD mice resulted in lower interstitial fibrosis than controls. There was a significant difference between renal tissue fibrosis in the simvastatin group at a dose of 5.2 mg/kgBW (P1) with a dose of 10.4 mg/kgBW (P2) and a dose of 20.8 mg/kgBW (P3).

Conclusion: Simvastatin can improve kidney function and reduce the degree of renal fibrosis in animal models of CKD. Thus, it can be a therapeutic strategy for CKD.

References

  1. Charles C, Ferris AH. Chronic Kidney Disease. Prim Care. 2020;47(4):585-595.
  2. Duan JY, Duan GC, Wang CJ, Liu DW, Qiao YJ, Pan SK, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: A cross-sectional survey. BMC Nephrol. 2020;21(1):1–13.
  3. Hasan M, Sutradhar I, Gupta R Das, Sarker M. Prevalence of chronic kidney disease in South Asia: A systematic review 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1117 Public Health and Health Services. BMC Nephrol. 2018;19(1):291.
  4. Saber A, Tahami AN, Najafipour H, Azmandian J. Assessment of prevalence of chronic kidney disease and its predisposing factors in Kerman city. Nephrourol Mon. 2017;9(2):e41794.
  5. Moreno Velásquez I, Tribaldos Causadias M, Valdés R, Gómez B, Motta J, Cuero C, et al. End-stage renal disease-financial costs and years of life lost in Panama: A cost-Analysis study. BMJ Open. 2019;9(5):e027229.
  6. Cahyawati PN, Lestari D, Siskayani A, Ariawan I. Simvastatin improves renal function and glomerulosclerosis in ischemic-reperfusion injury. Indones Biomed J. 2020;12(2):143–148.
  7. Cahyawati PN, Ngatidjan N, Sari DCR, Romi MM, Arfian N, Romi MM, et al. Simvastatin Attenuates Renal Failure in Mice With a 5/6 Subtotal Nephrectomy. Int J Pharm Pharm Sci. 2017;9(5):13–17.
  8. Mori Y, Hirano T. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol. Metabolism. 2012;61(3):379–388.
  9. Liu Y zhen, Liu M, Zhang Y ming, Kang L, Chen P zhi, Wang Z feng, et al. Protective Effects of Rosuvastatin in Experimental Renal Failure Rats via Improved Endothelial Function. Biol Res Nurs. 2013;15(3):356–364.
  10. Álvarez-Prats A, Hernández-Perera O, Díaz-Herrera P, Ucero ÁC, Anabitarte-Prieto A, Losada-Cabrera A, et al. Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy. Nephrol Dial Transplant. 2012;27(7):2720–2733.
  11. Hamasaki Y, Doi K, Okamoto K, Ijichi H, Seki G, Maeda-Mamiya R, et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Lab Investig. 2012;92(8):1161–1170.
  12. Rodrigues Díez R, Rodrigues-Díez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodríguez-Vita J, et al. Statins inhibit angiotensin II/smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One. 2010;5(11):e14145.
  13. Yue R, Zuo C, Zeng J, Su B, Tao Y, Huang S, et al. Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway. Ren Fail. 2017;39(1):643–651.
  14. Tristano AG, Fuller K. Immunomodulatory effects of statins and autoimmune rheumatic diseases: Novel intracellular mechanism involved. Int Immunopharmacol. 2006;6(12):1833–1846.
  15. Babelova A, Jansen F, Sander K, Löhn M, Schäfer L, Fork C, et al. Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. PLoS One. 2013;8(11):1–15.
  16. Bruder-Nascimento T, Callera G, Montezano AC, Antunes TT, He Y, Cat AND, et al. Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3. PLoS One. 2016;11(9):e0162731.
  17. Shibasaki M, Wang JG, Figueiredo JL, New SEP, Quillard T, Goettsch C, et al. Pitavastatin reduces inflammation in atherosclerotic plaques in apolipoprotein E-deficient mice with late stage renal disease. PLoS One. 2015;10(9):1–17.
  18. Annigeri R, Mani R. Acute interstitial nephritis due to statin and its class effect. Indian J Nephrol. 2015;25(1):54–56.
  19. Cahyawati PN. Effect of simvastatin on histopathology of the heart after 5/6 subtotal nephrectomy. Int J Appl Pharm. 2019;11(Special Issue 5):131–133.
  20. Cahyawati PN, Arfian N, Ngatidjan N. Effect of statin on vascular wall thickness in kidney disease model. IOP Conf Ser Mater Sci Eng. 2018;434(1).
  21. Maniam J, Morris MJ. The link between stress and feeding behaviour. Neuropharmacology. 2012;63(1):97–110.
  22. Francois M, Delgado IC, Shargorodsky N, Leu CS, Zeltser L. Assessing the effects of stress on feeding behaviors in laboratory mice. Elife. 2022;11:e70271.
  23. Chagnac A, Zingerman B, Rozen-Zvi B, Herman-Edelstein M. Consequences of glomerular hyperfiltration: The role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity. Nephron. 2019;143(1):38–42.
  24. Mirzoyan K, Baïotto A, Dupuy A, Marsal D, Denis C, Vinel C, et al. Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease. J Physiol Biochem. 2016;72(4):803–812.
  25. Cahyawati PN, Aryastuti AASA, Ariawan MBT, Arfian N, Ngatidjan N. Statin and anemia in chronic kidney disease (CKD): An experimental study. MATEC Web Conf. 2018;197:1–4.
  26. Cahyawati PN, Satriyasa BK. Subtotal Nephrectomy as a Model of Chronic Kidney Disease: A Systematic Review. Indian J Public Heal Res Dev. 2021;12(3):150–157.
  27. Nogueira A, Pires MJ, Oliveira PA. Pathophysiological mechanisms of renal fibrosis: A review of animal models and therapeutic strategies. In Vivo (Brooklyn). 2017;31(1):1–22.
  28. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 2014;124(6):2299–2306.
  29. Matovinović MS. 1. Pathophysiology and Classification of Kidney Diseases. Ejifcc. 2009;20(1):2–11.
  30. Grynberg K, Ma FY, Nikolic-Paterson DJ. The JNK signaling pathway in renal fibrosis. Front Physiol. 2017;8(OCT):1–12.
  31. Humphreys BD. Mechanisms of Renal Fibrosis. Annu Rev Physiol. 2018;80:6.1-6.18.
  32. Cherng S, Young J, Ma H. Alpha-Smooth Muscle Actin ( α -SMA). J Am Sci. 2008;4(4):7–9.
  33. Novakovic ZS, Durdov MG, Puljak L, Saraga M, Ljutic D, Filipovic T, et al. The interstitial expression of alpha-smooth muscle actin in glomerulonephritis is associated with renal function. Med Sci Monit. 2012;18(4):235–240.
  34. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338.
  35. Worung IM, Lestari AAW, Kandarini Y, Wande IN, Wirawati IAP, Mahartini IN. Correlation between serum levels of Fibroblast Growth Factor-23 (FGF-23) and parathyroid hormone levels in predialysis Chronic Kidney Disease (CKD) patients at Sanglah General Hospital, Bali, Indonesia. Bali Medical Journal. 2021;10(2):830-834.
  36. Kandarini Y, Widrhani V, Lestari AAWD. The correlation between serum fibroblast growth factor-23 with urinary fractional excretion of phosphate in predialysis chronic kidney disease. Bali Medical Journal. 2020;9(3):884-887.
  37. Satriyasa BK. Aqueous extract of purple sweet potato tubers decrease MDA and increase SOD2 in kidney of diabetic rats. Bali Medical Journal. 2016;5(3):388-390.

How to Cite

Cahyawati, P. N., I Nyoman Mantik Astawa, Bagus Komang Satriyasa, & I Made Bakta. (2023). Simvastatin: a new therapeutic strategy for Chronic Kidney Disease (CKD). Bali Medical Journal, 12(2), 2223–2238. https://doi.org/10.15562/bmj.v12i2.4636

HTML
21

Total
12

Share

Search Panel

Putu Nita Cahyawati
Google Scholar
Pubmed
BMJ Journal


I Nyoman Mantik Astawa
Google Scholar
Pubmed
BMJ Journal


Bagus Komang Satriyasa
Google Scholar
Pubmed
BMJ Journal


I Made Bakta
Google Scholar
Pubmed
BMJ Journal